https://www.avient.com/sites/default/files/2023-06/AVNT June IR Conferences w_Non GAAP Recs.pdf
GUIDANCE (TOTAL COMPANY) 11 $845 $846 Guidance Actual $125 $134 Guidance Actual Sales Adjusted EBITDA (in millions) $0.55 $0.63 Guidance Actual Adjusted EPS (in millions) Q1 2023 PERFORMANCE VS.
Avient reflects 2023 adjusted EBITDA guidance of $530M and estimated run-rate CAPEX of $110M.
Avient Specialty Formulators Other Specialty / Chemical Companies 2023E(%) 37 79 89 83 81 76 73 90 82 77 76 74 70 58 22 A vi en t K W R P P G F U L A V Y R P M F M C C E H X L A S H E C L H U N E M N S C L MULTIPLE EXPANSION Avient Specialty Formulators Other Specialty / Chemical Companies Source: Peer data per Bloomberg as of May 31, 2023 Note: Avient reflects 2023 adjusted EBITDA guidance of $530M and closing share price of $36.50.